Trastuzumab (anti-HER2)

Trastuzumab (PBS) is a humanized IgG1 monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab (PBS) has the potential for HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer research.

Product Specifications

CAS Number

[180288-69-1]

Product Name Alternative

Anti-Human HER2, Humanized Antibody (PBS)

UNSPSC

12352203

Hazard Statement

H302, H315, H319, H335

Target

ADC Antibody; EGFR

Type

Inhibitory Antibodies

Related Pathways

Antibody-drug Conjugate/ADC Related; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/trastuzumab-anti-her2.html

Purity

99.72

Solubility

10 mM in DMSO

Smiles

[Trastuzumab(anti-HER2)]

Molecular Weight

(145.42 kDa)

Precautions

H302, H315, H319, H335

References & Citations

[1]Sliwkowski MX, et al. Nonclinical studies addressing the mechanism of action of trastuzumab. Semin Oncol. 1999 Aug;26 (4 Suppl 12) :60-70.|[2]Hudis CA, et al. Trastuzumab--mechanism of action and use in clinical practice. N Engl J Med. 2007 Jul 5;357 (1) :39-51.|[3]Barok M, et al. Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance. Mol Cancer Ther. 2007 Jul;6 (7) :2065-72.